Ardelyx, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ardelyx, Inc. (ARDX) is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class medicines that address significant unmet medical needs in gastrointestinal and nephrology indications. The company offers two approved products in the United States: IBSRELA (tenapanor), a minimally absorbed small molecule sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults; and XPHOZAH (tenapanor), an NHE3 inhibitor for the reduction of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis. Ardelyx maintains a pipeline including RDX013, a small molecule potassium secretagogue for hyperkalemia; RDX020, a small molecule for metabolic acidosis; and RDX10531, a next-generation NHE3 inhibitor in preclinical development with potential applications across multiple therapeutic areas. Founded in 2007 and headquartered in Waltham, Massachusetts, with additional facilities in Newark, California, and Milwaukee, Wisconsin, Ardelyx operates primarily in the U.S. market while pursuing international commercialization through strategic partnerships, including agreements with Kyowa Kirin, Fosun Pharma and Knight Therapeutics for tenapanor outside the United States. In recent developments, Ardelyx reported third-quarter 2025 net product sales of $78.2 million for IBSRELA, up 92% year-over-year, and raised full-year 2025 guidance to $270-$275 million; secured a commercial supply agreement with Catalent Pharma Solutions for IBSRELA extending through 2028; appointed Eric Foster as Chief Commercial Officer to oversee strategies for its products; presented real-world evidence on XPHOZAH demonstrating patient satisfaction and phosphate reduction at ASN Kidney Week in November 2025; and initiated preclinical development of RDX10531 to support an investigational new drug submission in 2026.
Ardelyx Stock Up 70%: What to Know About This $490,000 Insider Transaction
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
Ardelyx: Low Price, But High Implied Valuation
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings
Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should Know
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Ardelyx President and CEO Sells 41,000 Shares for $243,000
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
Ardelyx to Participate in Upcoming Investor Conferences